Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IntraPace Inc.

www.intrapace.com

Latest From IntraPace Inc.

Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions

Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.

Medical Device Innovation

Device Start-Ups Inch Closer To Elusive Epilepsy Treatment

Despite the availability of more than 20 anti-epilepsy drugs, surgery, and a neurostimulation therapy that’s been available for 15 years, a large proportion of the three million patients in the US with epilepsy continue to have seizures. Emerging device companies aim to provide a solution for them.

Medical Device

Appetite for Obesity Devices Stays Strong

Numerous physiologic pathways lead to obesity; those related to hunger, satiety, the breakdown and absorption of nutrients, and the regulation of energy. Given the complexity of obesity, it's not surprising that diet and exercise aren't currently effective and that drugs have had only modest success. Bariatric surgery, on the other hand, which reduces the size of the stomach (and, in some versions, also reroutes part of the small intestine so that food bypasses it) is extremely successful. Many patients that have undergone the Roux-en-Y gastric bypass procedure have sustained losses of 50% of their excess weight out to ten years and beyond. Now companies with minimally invasive devices for the treatment of obesity hope to fill the therapy gap between dieting and invasive surgery. It's too early to claim victory, but start-ups and scientists are benefiting from a better understanding of why gastric bypass surgery works.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover use of fractional flow reserve PCI to avoid unecessary stenting; new European Society of Cardiology guidelines that should increase the use of implantable loop recorders; treating obesity with neurostimulation devices; Asthmatx's positive recommendation from an FDA panel; and the decrease in the number of 510(k) clearances.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • IntraPace Inc.
  • Senior Management
  • Chuck Brynelsen, CEO
    Bart Bandy, Chief Commercial Officer
    Gary Castro, VP, Fin. & Admin.
    Vince Kapral, Senior Dir., R&D
  • Contact Info
  • IntraPace Inc.
    Phone: (650) 316-4070
    967 N. Shoreline Blvd.
    Mountain View, CA 94043
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register